{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-012846","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.834030+00:00","generated_at":"2026-05-27T03:36:19.328807+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pyxis Oncology initiates combo trial PYX-201 + Keytruda and monotherapy expansion in HNSCC","bullets":["Phase 1/2 combo trial PYX-201-102 with Keytruda (pembrolizumab) in multiple solid tumors including R/M HNSCC, HR+/HER2- BC, TNBC; first dosing on track for Q1 2025.","Part 2 monotherapy expansion cohorts of Phase 1 PYX-201-101 began enrolling for 2L/3L R/M HNSCC patients who received prior platinum and PD-1 or EGFR and PD-1 inhibitors.","PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin (EDB+FN) in tumor extracellular matrix, designed to induce immunogenic cell death.","Combo trial is part of a Clinical Trial Collaboration Agreement with Merck (MRK)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-012846","json":"https://secwatch.observer/filing/0000950170-25-012846.json","markdown":"https://secwatch.observer/filing/0000950170-25-012846.md","text":"https://secwatch.observer/filing/0000950170-25-012846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025012846/0000950170-25-012846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025012846/pyxs-20250204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:36:19.328807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}